Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy
Lymphedema is a potential complication of breast cancer treatment. This longitudinal substudy aimed to prospectively assess arm measurements and symptoms following neoadjuvant chemotherapy and axillary dissection in the ACOSOG/Alliance Z1071 trial to characterize the optimal approach to define lymphedema.
Z1071 enrolled patients with cT0-4, N1-2, M0 disease treated with neoadjuvant chemotherapy. All patients underwent axillary dissection. Bilateral limb volumes, circumferences, and related symptoms were assessed pre-surgery, 1–2 weeks post-surgery, and semiannually for 36 months. Lymphedema definitions included volume increase ≥ 10% or limb circumference increase ≥ 2 cm. Symptoms were assessed by the Lymphedema Breast Cancer Questionnaire.
In 488 evaluable patients, lymphedema incidence at 3 years by ≥ 10%-volume-increase was 60.3% (95% CI 55.0–66.2%) and by ≥ 2 cm-circumference increase was 75.4% (95% CI 70.8–80.2%). Symptoms of arm swelling and heaviness decreased from post-surgery for the first 18 months and then were relatively stable. The 3-year cumulative incidence of arm swelling and heaviness was 26.0% (95% CI 21.7–31.1%) and 30.9% (95% CI 26.3–36.3%), respectively. There was limited agreement between the two measurements (kappa 0.27) and between symptoms and measurements (kappa coefficients ranging from 0.05–0.09).
Lymphedema incidence by limb volume and circumference gradually increased over 36 months post-surgery, whereas lymphedema symptoms were much lower. These findings underscore the importance of prospective surveillance and evaluation of both limb measurements and symptom assessment. Lymphedema incidence rates varied by definition. We recommend that ≥ 10% volume change criterion be used for lymphedema evaluation for referral for specialist care.
KeywordsLymphedema Clinical trials Neoadjuvant chemotherapy Prospective surveillance Breast cancer survivorship
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number UG1CA189823 (Alliance for Clinical Trials in Oncology NCORP Grant), U10CA180821, U10CA180882, U10CA180790, U10CA180858, U10CA180868, and U10CA180888
Compliance with ethical standards
This research was carried out in full compliance with ethical standards for research conducted with human subjects.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Conflict of interest
The authors declare no conflicts of interest. The authors have no financial relationship with the organization that sponsored the research. The authors have full control of all primary data and agree to allow the journal to review the source data, if requested.
- 1.American Cancer Society (2018) Breast Cancer Facts & Figures 2017–2018. America Cancer Society. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-042725.pdf. Accessed 30 June 2018
- 5.Fu MR, Ridner SH, Armer J (2009) Post-breast cancer lymphedema: part 2. Am J Nurs 109(8):34–41; quiz 42. https://doi.org/10.1097/01.NAJ.0000358492.91678.78 CrossRefPubMedGoogle Scholar
- 6.Nguyen TT, Hoskin TL, Habermann EB, Cheville AL, Boughey JC (2017) Breast Cancer-related lymphedema risk is related to multidisciplinary treatment and not surgery alone: results from a large cohort study. Ann Surg Oncol 24:2972–2980. https://doi.org/10.1245/s10434-017-5960-x CrossRefPubMedPubMedCentralGoogle Scholar
- 7.McLaughlin SA, DeSnyder SM, Klimberg S, Alatriste M, Boccardo F, Smith ML, Staley AC, Thiruchelvam PTR, Hutchison NA, Mendez J, MacNeill F, Vicini F, Rockson SG, Feldman SM (2017) Considerations for clinicians in the diagnosis, prevention, and treatment of breast cancer-related lymphedema, recommendations from an expert panel: part 2: preventive and therapeutic options. Ann Surg Oncol 24:2827–2835. https://doi.org/10.1245/s10434-017-5964-6 CrossRefPubMedGoogle Scholar
- 8.McLaughlin SA, Staley AC, Vicini F, Thiruchelvam P, Hutchison NA, Mendez J, MacNeill F, Rockson SG, DeSnyder SM, Klimberg S, Alatriste M, Boccardo F, Smith ML, Feldman SM (2017) Considerations for clinicians in the diagnosis, prevention, and treatment of breast cancer-related lymphedema: recommendations from a multidisciplinary expert ASBrS panel : part 1: definitions, assessments, education, and future directions. Ann Surg Oncol 24:2818–2826. https://doi.org/10.1245/s10434-017-5982-4 CrossRefPubMedGoogle Scholar
- 9.Norman SA, Localio AR, Potashnik SL, Simoes Torpey HA, Kallan MJ, Weber AL, Miller LT, DeMichele A, Solin LJ (2009) Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol 27(3):390–397. https://doi.org/10.1200/jco.2008.17.9291 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Hayes SC, Johansson K, Stout NL, Prosnitz R, Armer JM, Gabram S, Schmitz KH (2012) Upper-body morbidity after breast cancer: incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care. Cancer 118(8 Suppl):2237–2249. https://doi.org/10.1002/cncr.27467 CrossRefPubMedGoogle Scholar
- 13.Armer JM, Stewart BR, Smith K, Cormier JN (2011) Lymphedema following cancer treatment. In: Lester JL, Schmitt PA (eds) Cancer rehabilitation and survivorship: transdisciplinary approaches to personalized care. Oncology Nursing Society, PittsburghGoogle Scholar
- 16.Bulley C, Gaal S, Coutts F, Blyth C, Jack W, Chetty U, Barber M, Tan CW (2013) Comparison of breast cancer-related lymphedema (upper limb swelling) prevalence estimated using objective and subjective criteria and relationship with quality of life. Biomed Res Int 2013:807569–807568. https://doi.org/10.1155/2013/807569 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Nelson H, Hunt KK (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310(14):1455–1461. https://doi.org/10.1001/jama.2013.278932 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Medical Advisory Committee NLN (2013) Position paper: screening and measurement for early detection of breast cancer related lymphedema. Position statement of the National Lymphedema Network. National Lymphedema Network, San Francisco https://www.lymphnet.org/resources/position-paper-screening-and-measurement-for-early-detection-of-breast-cancer-related Google Scholar
- 21.National Accreditation Program for Breast Centers (2014) NAPBC standards manual 2014 edition. American College of Surgeons, Chicago https://www.facs.org/quality-programs/napbc/standards Google Scholar
- 23.Stout NL, Pfalzer LA, Springer B, Levy E, McGarvey CL, Danoff JV, Gerber LH, Soballe PW (2012) Breast cancer-related lymphedema: comparing direct costs of a prospective surveillance model and a traditional model of care. Phys Ther 92(1):152–163. https://doi.org/10.2522/ptj.20100167 CrossRefPubMedGoogle Scholar
- 27.Binkley JM, Harris SR, Levangie PK, Pearl M, Guglielmino J, Kraus V, Rowden D (2012) Patient perspectives on breast cancer treatment side effects and the prospective surveillance model for physical rehabilitation for women with breast cancer. Cancer 118(8 Suppl):2207–2216. https://doi.org/10.1002/cncr.27469 CrossRefPubMedGoogle Scholar
- 28.Petrek JA, Senie RT, Peters M, Rosen PP (2001) Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 92(6):1368–1377Google Scholar